<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04543812</url>
  </required_header>
  <id_info>
    <org_study_id>PBB00601</org_study_id>
    <nct_id>NCT04543812</nct_id>
  </id_info>
  <brief_title>PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD</brief_title>
  <official_title>A Phase 3 Study of PBF-1681 Comprising a 16-week, Placebo-controlled, Double-blind Randomized Period and an 8-week, Open-label Extension Period for the Treatment of Iron Deficiency Anemia in Patients With Non-Dialysis Dependent CKD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Panion &amp; BF Biotech Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Panion &amp; BF Biotech Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and effectiveness of PBF-1681 for the treatment of Iron Deficiency&#xD;
      Anemia in patients with Non-Dialysis Dependent Chronic Kidney Disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, 24-week, multicenter study in Taiwan, comprising a 16-week, randomized,&#xD;
      double-blind, placebo-controlled period (&quot;Randomized Period&quot;), followed by an 8-week&#xD;
      open-label extension period, where all subjects receive PBF-1681 (ferric citrate) (&quot;Extension&#xD;
      Period&quot;). The study will consist of 10 visits over a period of 24 weeks. There will be a&#xD;
      screening period of up to 14 days. Approximately 200 subjects will be randomized into the&#xD;
      Randomized Period in a 1:1 ratio to receive either PBF-1681 or matching placebo, at baseline.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects achieving an increase in Hgb of ≥1.0 g/dL at any time point between baseline and the end of the 16-week Randomized Period.</measure>
    <time_frame>16 weeks</time_frame>
    <description>Efficacy analyses were performed for the population consisted of all subjects who were randomized, had a baseline laboratory value, took at least 1 dose of study drug or placebo, and had at least 1 post-baseline laboratory assessment during the randomized period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (Hgb)</measure>
    <time_frame>16 weeks</time_frame>
    <description>The mean change from baseline to the end of the Randomized Period in Hgb.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferring saturation (TSAT)</measure>
    <time_frame>16 weeks</time_frame>
    <description>The mean change from baseline to the end of the Randomized Period in TSAT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ferritin</measure>
    <time_frame>16 weeks</time_frame>
    <description>The mean change from baseline to the end of the Randomized Period in ferritin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Phosphate</measure>
    <time_frame>16 weeks</time_frame>
    <description>The mean change from baseline to the end of the Randomized Period in serum phosphate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained increase in Hgb of ≥0.75 g/dL</measure>
    <time_frame>16 weeks</time_frame>
    <description>The proportion of subjects achieving a sustained increase in Hgb of ≥0.75 g/dL from baseline over any 4-week interval during the Randomization Period.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum calcium</measure>
    <time_frame>16 weeks</time_frame>
    <description>The mean change from baseline to the end of the Randomized Period in serum calcium.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum bicarbonate</measure>
    <time_frame>16 weeks</time_frame>
    <description>The mean change from baseline to the end of the Randomized Period in serum bicarbonate.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum iron</measure>
    <time_frame>16 weeks</time_frame>
    <description>The mean change from baseline to the end of the Randomized Period in serum iron.</description>
  </other_outcome>
  <other_outcome>
    <measure>Unsaturated iron binding capacity (UIBC)</measure>
    <time_frame>16 weeks</time_frame>
    <description>The mean change from baseline to the end of the Randomized Period in UIBC.</description>
  </other_outcome>
  <other_outcome>
    <measure>Total iron binding capacity (TIBC)</measure>
    <time_frame>16 weeks</time_frame>
    <description>The mean change from baseline to the end of the Randomized Period in TIBC.</description>
  </other_outcome>
  <other_outcome>
    <measure>Hematocrit</measure>
    <time_frame>16 weeks</time_frame>
    <description>The mean change from baseline to the end of the Randomized Period in hematocrit.</description>
  </other_outcome>
  <other_outcome>
    <measure>Intact parathyroid hormone (iPTH)</measure>
    <time_frame>16 weeks</time_frame>
    <description>The mean change from baseline to the end of the Randomized Period in iPTH.</description>
  </other_outcome>
  <other_outcome>
    <measure>Fibroblast growth factor 23 (intact and C-terminal)</measure>
    <time_frame>16 weeks</time_frame>
    <description>The mean change from baseline to the end of the Randomized Period in FGF23 (intact and C-terminal).</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum aluminum</measure>
    <time_frame>16 weeks</time_frame>
    <description>The mean change from baseline to the end of the Randomized Period in serum aluminum.</description>
  </other_outcome>
  <other_outcome>
    <measure>Sustained increase in Hgb</measure>
    <time_frame>16 weeks</time_frame>
    <description>The proportion of subjects achieving a sustained increase in Hgb of ≥0.75 g/dL from baseline over any 4-week interval during the Randomized Period, provided that an increase in Hgb of ≥1.0 g/dL had occurred during that 4-week interval</description>
  </other_outcome>
  <other_outcome>
    <measure>Increase in Hgb of ≥1.0 g/dL</measure>
    <time_frame>16 weeks</time_frame>
    <description>Time (in days) to first increase in Hgb of ≥1.0 g/dL from baseline.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Anemia of Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>PBF-1681 (ferric citrate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PBF-1681 (ferric citrate) will be dosed two times a day with the 2 largest meals (preferred) or three times a day with meals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo will be dosed two times a day with the 2 largest meals (preferred) or three times a day with meals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric citrate</intervention_name>
    <description>Ferric citrate will be provided as a 1g tablet. All intervention doses will be based on hemoglobin levels.</description>
    <arm_group_label>PBF-1681 (ferric citrate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo will be provided as a 1g tablet. All intervention doses will be based on hemoglobin levels.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men or women ≥18 years of age at screening.&#xD;
&#xD;
          2. CKD with eGFR &lt;60 mL/min at screening using the 4-variable Modification of Diet in&#xD;
             Renal Disease equation, where up to 20% of subjects with eGFR &lt;15 mL/min are allowed.&#xD;
&#xD;
          3. Hgb ≥9.0 g/dL and ≤11.5 g/dL at screening.&#xD;
&#xD;
          4. Serum ferritin &lt;300 ng/mL and TSAT &lt;30% at screening.&#xD;
&#xD;
          5. Serum iPTH ≤600 pg/mL at screening.&#xD;
&#xD;
          6. Must consume minimally 2 meals per day.&#xD;
&#xD;
          7. Willing to give written informed consent.&#xD;
&#xD;
          8. Women may be enrolled if they are:&#xD;
&#xD;
               1. Documented to be surgically sterile or postmenopausal (amenorrhea &gt;1 year and&#xD;
                  follicle-stimulating hormone ≥30 mU/mL), or&#xD;
&#xD;
               2. Practicing true abstinence for at least 28 days prior to study drug&#xD;
                  administration until 30 days after study drug administration and having a&#xD;
                  negative serum pregnancy test at screening, or&#xD;
&#xD;
               3. Using 2 forms of highly effective contraception, out of which 1 should be a&#xD;
                  physical barrier (condom or diaphragm), and another method such as adequate&#xD;
                  hormonal method (eg, contraceptive implants, injectables, oral contraceptives) or&#xD;
                  non-hormonal methods (eg, intrauterine device, spermicidals) from screening or at&#xD;
                  least 2 weeks prior to study drug administration (whichever is earlier) until 30&#xD;
                  days after the study drug administration and having a negative serum pregnancy&#xD;
                  test at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cause of anemia other than iron deficiency.&#xD;
&#xD;
          2. Serum phosphate &lt;3.5 mg/dL at screening.&#xD;
&#xD;
          3. IV iron administered within 4 weeks of the start of screening.&#xD;
&#xD;
          4. ESA administered within 4 weeks of the start of screening.&#xD;
&#xD;
          5. Blood transfusion within 4 weeks of the start of screening.&#xD;
&#xD;
          6. Liver enzymes (alanine aminotransferase [ALT]/aspartate aminotransferase [AST]) &gt;3&#xD;
             times upper limit of normal (ULN) at screening.&#xD;
&#xD;
          7. Symptomatic GI bleeding or symptomatic inflammatory bowel disease within 12 weeks of&#xD;
             the start of screening.&#xD;
&#xD;
          8. Concurrent GI diseases assessed by Investigators to be inappropriate for the study,&#xD;
             eg, acute peptic ulcer, chronic ulcerative colitis, and regional enteritis.&#xD;
&#xD;
          9. Active infection requiring systemic antimicrobial treatment such as antibiotics,&#xD;
             antiviral, or antifungals at screening.&#xD;
&#xD;
         10. Concomitant or prior malignancy, except non-melanoma skin cancer or disease-free for&#xD;
             ≥2 years after curative therapy.&#xD;
&#xD;
         11. Subjects with known allergic reaction to previous oral iron therapy.&#xD;
&#xD;
         12. Subjects who were intolerant to oral iron therapy.&#xD;
&#xD;
         13. History of hemochromatosis.&#xD;
&#xD;
         14. Scheduled kidney transplant or initiation of dialysis planned within 24 weeks of the&#xD;
             start of screening.&#xD;
&#xD;
         15. Planned surgery or hospitalization (anticipated to last &gt;72 hours) during the&#xD;
             Randomized Period of the study other than dialysis access-related surgery.&#xD;
&#xD;
         16. Any other medical condition that, in the Investigators' opinion, may disturb subject's&#xD;
             completion or optimal participation of the study, act as a significant confounding&#xD;
             variable, or carry significant risks to a subject.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Der-Cherng Tarng, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cindy Chiang</last_name>
    <phone>+886-2-2655-8218</phone>
    <phone_ext>302</phone_ext>
    <email>cchiang@pbf.com.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raymond Chuang, MS, PMP</last_name>
    <phone>+886-2-2655-8218</phone>
    <phone_ext>303</phone_ext>
    <email>rchuang@pbf.com.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>80756</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi-Wen Chiu, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Yi-Wen Chiu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang-Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chien-Te Lee, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Chien-Te Lee, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Nephrology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital</name>
      <address>
        <city>Keelung</city>
        <zip>20401</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ching-Chang Lee, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Ching-Chang Lee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Nephrology, Department of Internal Medicine, Far East Memorial Hospital</name>
      <address>
        <city>New Taipei City</city>
        <zip>22060</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu-Sen Peng, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Yu-Sen Peng, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Nephrology, Department of Internal Medicine, China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40433</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chiz-Tzung Chang, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Chiz-Tzung Chang, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Nephrology, Department of Internal Medicine, Taipei Medical University-Shuang Ho Hospital</name>
      <address>
        <city>Taipei county</city>
        <zip>23561</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mai-Szu Wu, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Mai-Szu Wu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Integrated Diagnostics and Therapeutics, National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chih-Kang Chiang, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Chih-Kang Chiang, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Nephrology, Department of Internal Medicine, Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Der-Cherng Tarng, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Der-Cherng Tarng, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 2, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ferric Citrate</keyword>
  <keyword>Anemia</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

